FCX-013

FCX-013 is an autologous gene therapy candidate designed for the treatment of localized scleroderma (morphea). It consists of autologous dermal fibroblasts that are genetically modified to express matrix metalloproteinase 1 (MMP-1), an enzyme responsible for breaking down Type I and Type III collagen. The expression of MMP-1 is regulated by Precigen's proprietary RheoSwitch Therapeutic System (RTS), a gene switch that allows for precise, dose-dependent control of protein expression through the administration of an oral activator ligand. By targeting the excessive collagen deposition characteristic of scleroderma lesions, FCX-013 aims to reduce skin thickening and improve joint mobility. The therapy was originally developed by Fibrocell Science in collaboration with Precigen and is currently under development by Castle Creek Biosciences following its acquisition of Fibrocell.